Survey Findings Presented at CTTI’s Webinar on May 20th, 2020
Evidation recently co-developed a survey with the Clinical Trials Transformation Initiative to rapidly understand how participants currently enrolled in clinical trials have been impacted by the COVID-19 pandemic. The survey was deployed through our virtual research community, Achievement, to 848 participants currently enrolled in clinical trials spanning 17 different therapeutic areas. The survey focused on how the pandemic has impacted individuals’ participation and experience in their clinical trials, including the communications they received from sites and study teams. Survey responses were collected from 5/8/2020 – 5/11/2020.
Evidation’s Bray Patrick-Lake presented the results during CTTI’s webinar on “Adapting Clinical Trials During COVID-19: Solutions for Switching to Remote and Virtual Visits.” Below are some of the key findings from the survey.
35% of the 848 individuals reported feeling worried or very worried about going to a hospital or clinic during the COVID-19 pandemic; 9% overall reported stopping their participation in their clinical trial because they worried about exposure to COVID-19. This concern was particularly salient for immunocompromised individuals; of the 258 individuals who are immunocompromised, 52% reported feeling worried or very worried about going to a hospital or clinic during the COVID-19 pandemic; 12.4% (32) reported stopping their participation in their clinical trial because they worried about exposure to COVID-19.
14% (121) of the participants were considering stopping their clinical trials for the following reasons:
Of the 335 participants who reported going to in-person visits to the research site or hospital before the pandemic, their trials changed in the following ways after the pandemic started:
8.4% of individuals felt dissatisfied with communications received from investigators or sites about how COVID-19 would impact their clinical trial; of those, 40% reported a desire to receive some communication as they didn’t receive any at all.
Bray Patrick-Lake encouraged sites and investigators to communicate with clinical trial participants about anticipated trial disruptions or changes as often and directly as possible.
COVID-19 has emphasized the need to develop direct connections with individuals. Frequent communication is crucial to understand their trial participation experience and how changes may impact them. These patient-centered practices should be incorporated into future and ongoing trials to ensure a seamless transition from site-based research to research conducted outside of clinic walls.